AQST
NASDAQAquestive Therapeutics Inc.
Price$4.00+0.02 (+0.50%)
01:30 PM07:45 PM
News · 26 weeks56-64%
2025-12-142026-06-07
Mix3090d
- Insider17(57%)
- SEC Filings7(23%)
- Other2(7%)
- Earnings2(7%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- INSIDERChief Commercial Officer Korczynski Sherry covered exercise/tax liability with 2,714 shares, decreasing direct ownership by 1% to 238,403 units (SEC Form 4) (for withholding tax)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Legal Officer Zalewski Thomas A. was granted 100,000 shares (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERPresident and CEO Barber Daniel sold $35,413 worth of shares (8,257 units at $4.29), decreasing direct ownership by 1% to 660,574 units (SEC Form 4)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSVP, Regulatory Affairs Cioffi Melina covered exercise/tax liability with 1,667 shares, decreasing direct ownership by 0.61% to 273,200 units (SEC Form 4) (withholding obligation)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- SECSEC Form 10-Q filed by Aquestive Therapeutics Inc.10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECAquestive Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- PRAquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateReaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United KingdomCompleted AQST-108 phase 1 study in subjects with androgenic alopecia with no safety issues observedEntered into a $150 million debt facility with Oaktree Capital Management, L.P.Company to host investor call on May 14, 2026, at 8:00am ET WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ
- PRAquestive Therapeutics Completes $150 Million Debt Refinancing with OaktreeWARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility with a new $150 million debt facility with funds managed by Oaktree Capital Management, L.P. ("Oaktree"). This transaction provides additional flexibility to fund the launch of Anaphylm™, if approved by the FDA. At closing, Oaktree provided $55.0 million, which was primarily used to repay the Company's existing loan in the aggregate principal amount of $45 mi
- INSIDERCorporate Secretary Braender Lori J covered exercise/tax liability with 135,690 shares, decreasing direct ownership by 37% to 231,042 units (SEC Form 4) to cover taxes4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief People Officer Boyd Peter E. covered exercise/tax liability with 56,778 shares, decreasing direct ownership by 17% to 281,731 units (SEC Form 4) (for tax liability)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERPresident and CEO Barber Daniel covered exercise/tax liability with 335,922 shares, decreasing direct ownership by 33% to 668,831 units (SEC Form 4) to cover withholding tax4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Financial Officer Toth A Ernest Jr covered exercise/tax liability with 92,652 shares, decreasing direct ownership by 25% to 283,460 units (SEC Form 4) (for tax liability)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERChief Operating Officer Jung Cassie covered exercise/tax liability with 72,734 shares, decreasing direct ownership by 26% to 202,246 units (SEC Form 4) (for tax liability)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERCorporate Secretary Braender Lori J covered exercise/tax liability with 76,147 shares, decreasing direct ownership by 17% to 366,732 units (SEC Form 4) (tax withholding)4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- PRAquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ETWARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2026 and provide an update on recent developments in its business after market close on Wednesday, May 13, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, May14, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of t
- SECSEC Form DEFA14A filed by Aquestive Therapeutics Inc.DEFA14A - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- SECSEC Form DEF 14A filed by Aquestive Therapeutics Inc.DEF 14A - Aquestive Therapeutics, Inc. (0001398733) (Filer)
- ANALYSTOppenheimer resumed coverage on Aquestive Therapeutics with a new price targetOppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00
- INSIDERSEC Form 4 filed by Barber Daniel4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Boyd Peter E.4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Jung Cassie4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Toth A Ernest Jr4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Korczynski Sherry4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
- INSIDERSEC Form 4 filed by Braender Lori J4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
AQST FAQ
7 questionsWhat does Aquestive Therapeutics Inc. do?
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The...Where does AQST stock trade?
Aquestive Therapeutics Inc. (AQST) is listed on NASDAQ.What sector and industry is AQST in?
Aquestive Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aquestive Therapeutics Inc. go public?
Aquestive Therapeutics Inc. (AQST) completed its IPO in 2018.What are analysts saying about AQST?
Aquestive Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $800.00 price target on 2026-04-24. Recent price targets range from $700.00 to $1700.00.What companies are similar to AQST?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AQST side-by-side with any of them on Quantisnow.How can I track AQST on Quantisnow?
Quantisnow aggregates Aquestive Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AQST to receive live email and push alerts on every new disclosure.